生育治疗后继发女性特异性恶性肿瘤发病率的荟萃分析伞状综述
该伞状综述检索多个数据库至2022年4月,纳入11篇荟萃分析(含188项研究),比较生育治疗组与未生育治疗组女性特异性恶性肿瘤发病率。结果显示生育治疗后卵巢癌(OR 1.21;95%CI 1.00-1.45)和卵巢交界性肿瘤(OR 1.87;95%CI 1.18-2.97)发病率显著升高,但无任何关联达到强或高度提示性证据等级。
要点
- 生育治疗后卵巢癌发病率升高(OR 1.21;95%CI 1.00-1.45)。
- 生育治疗后卵巢交界性肿瘤发病率升高(OR 1.87;95%CI 1.18-2.97)。
- 所考察的关联均未达到强或高度提示性证据等级。
核心结论
- 生育治疗与卵巢癌(包括卵巢交界性肿瘤)发病率升高存在关联。
- 生育治疗与女性特异性恶性肿瘤的关联仍存争议,因荟萃分析间结果矛盾。
- 所考察的关联均不能声称具有强或高度提示性证据。
研究设计与样本
- 伞状综述,检索Cochrane系统评价数据库、EMBASE、Google Scholar和PubMed,从建库至2022年4月。
- 从3129篇文献中纳入11篇荟萃分析综述,共含188项研究。
- 纳入标准要求治疗组(控制性卵巢刺激和/或体外受精(IVF)或卵胞浆内单精子注射)与对照组(未行生育治疗、一般人群)均报告各癌症亚组发病率。
主要发现
- 卵巢癌:生育治疗组1229/430611 vs 未生育治疗组27358/4263300(OR 1.21;95%CI 1.00-1.45)。
- 卵巢交界性肿瘤:生育治疗组117/414729 vs 未生育治疗组934/2626324(OR 1.87;95%CI 1.18-2.97)。
- 卵巢癌:生育治疗且具体行IVF者发病率更高(OR 1.65;95%CI 1.07-2.54)。
- 卵巢交界性肿瘤:仅用克罗米芬(CC)者OR 1.99(95%CI 1.02-3.87);仅用人绝经期促性腺激素者OR 3.46(95%CI 1.39-8.59);CC与人绝经期促性腺激素联合者OR 3.79(95%CI 1.47-9.77)。
- 采用统计学显著性阈值时,卵巢癌相关荟萃分析(随机效应法)仍具统计学显著性。
临床怎么用
- 作者认为这些发现具有重要临床意义,有助于为接受生育治疗的患者提供知情告知和有效咨询。
局限性
- 所考察的关联均不能声称具有强或高度提示性证据。
- 生育治疗与女性特异性恶性肿瘤的关联仍存争议,因荟萃分析间结果矛盾。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Understanding the potential risks associated with fertility treatments (FTs) can guide clinical decision and patient counseling. OBJECTIVE: To investigate the validity of the association between the development of female-specific malignancies including ovarian, endometrial, breast, and cervical cancer after FT. DATA SOURCES: A search of systematic reviews and meta-analyses was performed from inception to April 2022 within several databases: Cochrane Database of Systematic Reviews, EMBASE, Google Scholar, and PubMed. STUDY SELECTION AND SYNTHESIS: The inclusion criteria required the incidence of each cancer subgroup to be stated in both the defined treatment group (controlled ovarian stimulation and/or in vitro fertilization [IVF] or intracytoplasmic sperm injection) and the control group (no-FT, general population). From 3,129 identified publications, 11 meta-analytical reviews consisting of 188 studies were selected for synthesis. MAIN OUTCOME: The primary outcome of interest was incidence of each subgroup of cancer in the "FT" group compared with the "no-FT" group. RESULTS: A statistically significant increase in incidence of ovarian (1,229/430,611 in FT group vs. 27,358/4,263,300 in no-FT group) cancer (odds ratio [OR], 1.21; 95% confidence interval [CI], 1.00-1.45) and borderline ovarian tumors (117/414,729 in FT group vs. 934/2,626,324 in no-FT group) (OR, 1.87; 95% CI, 1.18-2.97) was observed. The incidence of ovarian cancer was higher with FT and IVF specifically (OR, 1.65; 95% CI, 1.07-2.54). For borderline ovarian tumors, the incidence was higher, not only with FT overall and IVF, but also according to the fertility drug regimen applied: clomiphene citrate (CC) only (OR, 1.99; 95% CI, 1.02-3.87), human menopausal gonadotropin only (OR, 3.46; 95% CI, 1.39-8.59), and CC and human menopausal gonadotropin combined (OR, 3.79; 95% CI, 1.47-9.77). When using the threshold for statistical significance, the meta-analyses relevant to ovarian cancers remained statistically significant (random-effects method). However, none of the examined associations could claim either strong or highly suggestive evidence. CONCLUSION AND RELEVANCE: An observed association between ovarian cancer (including borderline ovarian tumors) and FT has been demonstrated. The association between FT and female-specific malignancy remains a contentious topic because there have been contradictory outcomes among meta-analyses. This umbrella review interrogates existing systematic reviews and meta-analyses on this topic and concludes that a statistically significant increase in the incidence of ovarian cancer and borderline ovarian tumors is associated with FT. These findings have a significant clinical impact because it helps to inform and provide effective counseling for patients undergoing FT.
引用
- Saso S, Barcroft JF, Kasaven LS, et al. An umbrella review of meta-analyses regarding the incidence of female-specific malignancies after fertility treatment. Fertil Steril. 2024. PMID: 39545878. doi:10.1016/j.fertnstert.2024.09.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。